Aging Global Population And Advanced Neurostimulation Will Expand Treatment Options
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 8 Analysts
Published
17 Aug 25
Updated
21 Aug 25
AnalystHighTarget's Fair Value
US$20.00
56.7% undervalued intrinsic discount21 Aug
US$8.66
1Y
16.6%7D
-7.1%